N-甲基吗啉盐酸盐 - CAS号 3651-67-0

物化性质

熔点：

203-211 °C
稳定性/保质期：

在常温常压下保持稳定。

计算性质

辛醇/水分配系数(LogP)：

-0.03
重原子数：

8
可旋转键数：

0
环数：

1.0
sp3杂化的碳原子比例：

1.0
拓扑面积：

12.5
氢给体数：

1
氢受体数：

2

安全信息

危险品标志：

Xi
安全说明：

S22,S24/25
危险类别码：

R36/37/38
海关编码：

2934999090
危险性防范说明：

P261,P305+P351+P338
危险性描述：

H302,H315,H319,H335
储存条件：

请将药品存放在避光、通风干燥的地方，并密封保存。

SDS

SDS：0e77944ba9b91c4cf21560c003af4c21

查看

Name:	N-Methylmorpholine hydrochloride 99+% Material Safety Data Sheet
Synonym:	None listed
CAS:	3651-67-0

Section 1 - Chemical Product MSDS Name:N-Methylmorpholine hydrochloride 99+% Material Safety Data Sheet
Synonym:None listed

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3651-67-0	N-Methylmorpholine hydrochloride	99+	222-893-8

Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation. Use with adequate ventilation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3651-67-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 207.00 - 211.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: soluble
Specific Gravity/Density: Not available.
Molecular Formula: C5H11NO.HCl
Molecular Weight: 137.61

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3651-67-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N-Methylmorpholine hydrochloride - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 3651-67-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3651-67-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3651-67-0 is not listed on the TSCA inventory.
It is for research and development use only.

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

作为反应物：

描述：

N-甲基吗啉盐酸盐生成 N-甲基哌嗪

参考文献：

名称：

Ishiguro et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1953, vol. 73, p. 1110,1111,1113

摘要：

DOI：
作为产物：

描述：

N-甲基吗啉在盐酸作用下，以甲醇、乙醇为溶剂，生成 N-甲基吗啉盐酸盐

参考文献：

名称：

羧基邻苯二甲酸酯对胺的还原烷基化作用

摘要：

我们首次证明了羧酸原酸酯可以在胺的还原烷基化中用作烷基化剂。使用标准的多相催化剂，将多种胺（包括氨基酸酯）进行烷基化，从而以高产率实际可行地以高选择性生成单烷基化产物。通过施加无环原酸酯，在室温下完成烷基化。

DOI：

10.1002/adsc.202000510
作为试剂：

描述：

Boc-L-天冬氨酸 4-苄酯在 N-甲基吗啉、 N-甲基吗啉盐酸盐、 1-羟基苯并三唑、 N,N'-二环己基碳二亚胺、三氟乙酸作用下，以二氯甲烷、 N,N-二甲基甲酰胺为溶剂，反应 32.05h，生成 Tyr-D-Ala-Phe-Asp(OBzl)-Val-Val-Gly-NH2

参考文献：

名称：

Unique sequence in deltorphin C confers structural requirement for δ opioid receptor selectivity

摘要：

A series of deltorphin C (H-Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2) analogues were synthesized to assess the consequences of changing anionic and hydrophobic residues on delta receptor selectivity. Analogues with altered C-terminal groups, inverted sequences, or esterified with tert-butyl, benzyl, or ethyl groups revealed that high delta selectivity required an unmodified amino acid sequence. Shifts of Asp and hydrophobic residues decreased delta selectivity due to loss in delta affinity (5- to almost-equal-to 700-fold); mu affinity was unchanged or increased 14-fold. Suppression of charge or deamidation diminished delta selectivity through reduced delta and modified mu affinities. Data provide evidence that a negative charge does not a priori guarantee high selectivity and specific alignment of anionic and hydrophobic residues might facilitate optimum spatial configuration which complements the 8 receptor binding site.

DOI：

10.1016/0223-5234(92)90113-f

点击查看最新优质反应信息

文献信息

N-Monomethylation of amines using paraformaldehyde and H<sub>2</sub>

作者：Hongli Wang、Yongji Huang、Xingchao Dai、Feng Shi

DOI：10.1039/c7cc02314f

日期：——

N-monomethylation of amines is an important topic in fine chemical synthesis. Herein, for the first time, we described a selective N-monomethylation reaction of amines with paraformaldehyde and H2 in the presence of a CuAlOx catalyst. A variety of amines, including primary aromatic amines, benzylamine and cyclohexylamine, as well as secondary amines, have been shown to be compatible with this reaction.

胺的选择性N-单甲基化是精细化学合成中的重要课题。在此，我们首次描述了在CuAlO x催化剂存在下胺与多聚甲醛和H 2的选择性N-单甲基化反应。已经显示出多种胺，包括伯芳族胺，苄基胺和环己胺，以及仲胺与该反应相容。
IAP ANTAGONISTS

申请人：BRISTOL-MYERS SQUIBB COMPANY

公开号：US20160376307A1

公开（公告）日：2016-12-29

There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

披露了调节凋亡抑制因子（IAPs）活性的化合物，包含该化合物的药物组合物以及利用本发明的化合物治疗增生性疾病和凋亡失调疾病，如癌症的方法。
MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

申请人：DOW AGROSCIENCES LLC

公开号：US20130296371A1

公开（公告）日：2013-11-07

The disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides.

该披露涉及到式I的大环吡啶酰胺及其作为杀菌剂的用途。
[EN] 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS<br/>[FR] DÉRIVÉS D'ACIDES 3-PHÉNYL-4-HEXINOÏQUES EN TANT QU'AGONISTES DE GPR40

申请人：CELON PHARMA SA

公开号：WO2019134984A1

公开（公告）日：2019-07-11

A compound of the formula (I)wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3–C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3–C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom,and* denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes. (I)

式（I）的化合物，其中R代表直链或支链、一次或二次脂肪族C3-C15基团，可以是饱和或不饱和，或者直链或支链、一次或二次脂肪族C3-C15基团，可以是饱和或不饱和，其中一个或多个氢原子被氟原子取代；X代表氢原子或卤素原子，*表示手性中心，以及其盐。该化合物对于治疗由GPR40介导的疾病，特别是II型糖尿病，具有用处。
[EN] ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KINASE ATM ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI

申请人：CHDI FOUNDATION INC

公开号：WO2021113506A1

公开（公告）日：2021-06-10

Provided are certain ATM kinase inhibitors of Formula (I). Also provided herein are compositions of such compounds, and methods of their use.

提供了某些Formula (I)的ATM激酶抑制剂。本文还提供了这些化合物的组合物，以及它们的使用方法。

N-甲基吗啉盐酸盐 | 3651-67-0

分子结构分类

物化性质

计算性质

安全信息

SDS

反应信息

文献信息

同类化合物

相关结构分类

热门分子